The BMJ Establishes an Independent Panel to Review Statin Articles
Draft terms of reference and membership of panel now on bmj.com
An independent panel has now been established to review two articles published in The BMJ by John Abramson and colleagues and Aseem Malhotra. Last week, the authors withdrew a statement in their articles about the side effects of statins after it was found to be incorrect.
The draft terms of reference and membership of the panel are now available on bmj.com.
The panel will be chaired by Iona Heath, former chair of the Royal College of General Practitioners and of The BMJ’s ethics committee, and will have six other members:
Stephen Evans, professor of pharamcoepidemiology at the London School of Hygeine and Tropical Medicine
Curt Furberg, professor emeritus of public health sciences at Wake Forest University School of Medicine, North Carolina
Julia Hippisley-Cox, professor of epidemiology and general practice at the University of Nottingham
Harlan Krumholz, Harold H. Hines Jr. professor of medicine (cardiology) and professor of investigative medicine and of public health (health policy) at Yale School of Medicine
Cynthia Mulrow, senior deputy editor at Annals of Internal Medicine and adjunct professor of medicine at Texas University of Health Science Center
Paul Wilks, vice president of innovation, Patients Like Me
The panel’s remit will be to consider whether either or both articles should be retracted and to review and comment on the process by which the articles were published. The panel will also review and comment on how criticisms and complaints against the articles were raised, and how the journal responded.
The panel will then make recommendations to The BMJ's editor in chief in a report by 31 July 2014 that will be published on bmj.com.
To ensure full accountability and transparency, all submissions to the panel and all documents used by the panel will be placed in the public domain on bmj.com, either at the time of submission or as part of the panel's final report.
Panel members and all those submitting information to the panel will also make full declarations of their interests, which will also be published on bmj.com.
Read full details here: http://www.bmj.com/about-bmj/independent-statins-review-panel
To comment on the draft please email [email protected] by Friday 23 May 2014
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
